Ignite Creation Date:
2024-05-05 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00484601
Status:
TERMINATED
Last Update Posted:
2019-02-11
First Post:
2007-06-08
Brief Title:
Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma
Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Overview
Official Title:
Phase II Study of Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma
Status:
TERMINATED
Status Verified Date:
2019-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Low accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research is to test the effectiveness and toxicity of both Ifosfamide and Doxorubicin It also aims to explore the relationship between EBV DNA and clinical response in patients with advanced naso-pharyngeal cancer which has been previously treated with chemotherapy
Detailed Description:
Nasopharyngeal Cancer NPC is one of the common cancer in Southeast Asia In this region NPC is associated with Epstein Barr Virus EBV chronic infection with EBV DNA identifiable in almost all the NPC tumors and patients serum at the time of diagnosis Chinese especially cantonese has the highest incidence Only about 30 of patients presents early disease and has a good treatment outcome 80 cure for stage I disease and 70 for stage II by radiation
This research is to test the effectiveness and toxicity of both Ifosfamide and Doxorubicin It also aims to explore the relationship between EBV DNA and clinical response in patients with advanced naso-pharyngeal cancer which has been previously treated with chemotherapy
Investigators believe EBV infection is necessary to cause NPC and that EBV DNA levels in the blood may directly relate to the total size of the tumor Because NPC patients in this situation have a poor outlook we design this study to evaluate the combination of Ifosfamide and doxorubicin for further treatment While this combination of medicines has been used in many other forms of cancer it has not been tested in patients with NPC
This research is to test the effectiveness and toxicity of both Ifosfamide and Doxorubicin It also aims to explore the relationship between EBV DNA and clinical response in patients with advanced naso-pharyngeal cancer which has been previously treated with chemotherapy
Investigators believe EBV infection is necessary to cause NPC and that EBV DNA levels in the blood may directly relate to the total size of the tumor Because NPC patients in this situation have a poor outlook we design this study to evaluate the combination of Ifosfamide and doxorubicin for further treatment While this combination of medicines has been used in many other forms of cancer it has not been tested in patients with NPC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 03-09-11-08 | OTHER | JHM IRB | None |